Table 4.

Univariate analysis of clinicopathologic and molecular factors

Variable5y-RFS (95% CI)P5y-OS (95% CI)P
Histotype0.0280.001
 UPS74% (61–87)86% (76–96)
 Synovial sarcoma43% (23–64)55% (35–76)
 Other49% (32–67)45% (28–62)
Location0.110.21
 Lower limbs61% (49–73)67% (56–78)
 Upper limbs43% (23–64)50% (29–71)
 Trunk wall86% (60–100)86% (60–100)
Size0.360.33
 5–9.9 cm65% (46–83)72% (54–90)
 ≥10 cm53% (38–68)61% (47–76)
P-gp0.750.29
 Positive60% (48–72)61% (49–73)
 Negative55% (38–71)70% (52–87)
GSTpi0.610.74
 Positive65% (42–87)61% (38–86)
 Negative56% (45–68)64% (53–75)
MRP10.0290.21
 Positive23% (0–49)44% (11–76)
 Negative64% (52–73)67% (57–77)
Response (RECIST)0.570.11
 SD58% (43–73)72% (59–85)
 PR50% (28–72)54% (31–76)
 PD60% (17–100)50% (11–89)
MRP1 quartiles:0.0520.065
 1st quartile59% (37–82)55% (32–77)
 2nd quartile75% (56–94)83% (54–100)
 3rd quartile60% (38–82)65% (45–86)
 4th quartile33% (11–55)41% (18–63)
MRP1:0.0120.032
 1st to 3rd quartile65% (53–77)68% (55–80)
 4th quartile33% (12–55)41% (18–63)
Combined ABCC1/MRP1a0.0030.025
 Negative69% (56–81)70% (58–82)
 Positive/highest33% (14–52)40% (19–61)

Abbreviations: UPS, undifferentiated pleomorphic sarcoma; PR, partial response; SD, stable disease; PD, progressive disease.

  • aPositive/highest includes cases with positive immunostaining MRP1 or ABCC1expresion of the 4th quartile.